- Home
- BURL vs BIIB Comparison
BURL vs BIIB Comparison
Compare BURL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BURL
- BIIB
- Stock Information
- Founded
- BURL 1972
- BIIB 1978
- Country
- BURL United States
- BIIB United States
- Employees
- BURL N/A
- BIIB N/A
- Industry
- BURL Department/Specialty Retail Stores
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- BURL Consumer Discretionary
- BIIB Health Care
- Exchange
- BURL Nasdaq
- BIIB Nasdaq
- Market Cap
- BURL 17.4B
- BIIB 18.7B
- IPO Year
- BURL 2013
- BIIB 1991
- Fundamental
- Price
- BURL $272.73
- BIIB $128.00
- Analyst Decision
- BURL Strong Buy
- BIIB Buy
- Analyst Count
- BURL 14
- BIIB 27
- Target Price
- BURL $318.64
- BIIB $188.17
- AVG Volume (30 Days)
- BURL 890.8K
- BIIB 1.2M
- Earning Date
- BURL 08-28-2025
- BIIB 07-31-2025
- Dividend Yield
- BURL N/A
- BIIB N/A
- EPS Growth
- BURL 37.20
- BIIB 31.67
- EPS
- BURL 8.16
- BIIB 10.45
- Revenue
- BURL $10,768,539,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- BURL $9.77
- BIIB N/A
- Revenue Next Year
- BURL $9.72
- BIIB N/A
- P/E Ratio
- BURL $33.42
- BIIB $12.24
- Revenue Growth
- BURL 8.34
- BIIB 3.36
- 52 Week Low
- BURL $212.92
- BIIB $110.04
- 52 Week High
- BURL $298.89
- BIIB $219.44
- Technical
- Relative Strength Index (RSI)
- BURL 59.15
- BIIB 47.82
- Support Level
- BURL $274.44
- BIIB $125.97
- Resistance Level
- BURL $288.59
- BIIB $133.05
- Average True Range (ATR)
- BURL 6.94
- BIIB 3.65
- MACD
- BURL 0.79
- BIIB -0.27
- Stochastic Oscillator
- BURL 61.04
- BIIB 48.33
About BURL Burlington Stores Inc.
Burlington Stores Inc is off-price retailer offering an extensive selection of in-season, fashion-focused merchandise including: women's ready-to-wear apparel, menswear, youth apparel, baby, beauty, footwear, accessories, home, toys, gifts and coats. Company sell a broad selection of desirable, first-quality, current-brand, labeled merchandise acquired directly from nationally recognized manufacturers and other suppliers. Company sell product in category such as Ladies apparel, Accessories and shoes, Home, Mens apparel, Kids apparel and baby and Outerwear.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.